Payment overview · 2025
General Payments
$574.60
29 reported records · 14 companies
Healthcare provider profile · identity verified
Amanda Neline Hale, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · DURANT, OK · NPI 1699215780
Verified facts
What the public records show
CMS Open Payments records show Amanda Neline Hale, D.O. received $574.60 in general payments during 2025 across 29 reported records.
Sumitomo Pharma America, Inc. accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $114.84 | 20.0% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.58 | 19.6% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $60.19 | 10.5% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $48.28 | 8.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.37 | 8.1% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $45.37 | 7.9% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $25.01 | 4.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.72 | 4.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.52 | 3.2% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $17.96 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.08 | 3.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.92 | 2.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.41 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.35 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $574.60 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $114.84 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.58 | 5 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $60.19 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48.28 | 3 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $46.37 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $38.56 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.72 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 49 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 207 | 78 |
| Lisinopril | Lisinopril | 185 | 59 |
| Losartan Potassium | Losartan Potassium | 169 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 132 | 46 |
| Gabapentin | Gabapentin | 121 | 37 |
| Furosemide | Furosemide | 113 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 33 |
| Meloxicam | Meloxicam | 109 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 30 |
| Omeprazole | Omeprazole | 104 | 31 |
| Metformin Hcl | Metformin Hcl | 97 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 17 |
| Potassium Chloride | Potassium Chloride | 77 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 16 |
| Donepezil Hcl | Donepezil Hcl | 57 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 22 |
| Eliquis | Apixaban | 50 | 16 |
| Montelukast Sodium | Montelukast Sodium | 49 | 18 |
| Ozempic | Semaglutide | 49 | 12 |
| Alendronate Sodium | Alendronate Sodium | 48 | 16 |
| Pregabalin | Pregabalin | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 21 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Simvastatin | Simvastatin | 41 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 14 |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 11 |
| Trazodone Hcl | Trazodone Hcl | 38 | 14 |
| Allopurinol | Allopurinol | 37 | 11 |
| Clonazepam | Clonazepam | 37 | 11 |
| Rybelsus | Semaglutide | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Alprazolam | Alprazolam | 34 | 15 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | 11 |
| Carvedilol | Carvedilol | 32 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | 14 |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 12 |
| Temazepam | Temazepam | 28 | suppressed |
| Ezetimibe | Ezetimibe | 27 | 13 |
| Famotidine | Famotidine | 27 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 24 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 13 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Cephalexin | Cephalexin | 15 | 12 |
| Glipizide | Glipizide | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Lorazepam | Lorazepam | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Enbrel Sureclick | Etanercept | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $574.60 · 29 records | Sumitomo Pharma America, Inc. | ARISTADA, CAPLYTA, GEMTESA, INCEPTIV, INVEGA SUSTENNA, LYBALVI, MAVYRET, NURTEC ODT, OTEZLA, Ozempic, PROCLAIM, RELISTOR, REPATHA, REXULTI, ZAVZPRET, ZENPEP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error